Robert Boden

Summary

Affiliation: Uppsala University
Country: Sweden

Publications

  1. doi Five-year outcome of first-episode psychosis before and after the implementation of a modified assertive community treatment programme
    Robert Boden
    Department of Neuroscience, Psychiatry Ulleraker, Uppsala University Hospital, 750 17, Uppsala, Sweden
    Soc Psychiatry Psychiatr Epidemiol 45:665-74. 2010
  2. pmc A comparison of cardiovascular risk factors for ten antipsychotic drugs in clinical practice
    Robert Boden
    Department of Neuroscience, Psychiatry, Uppsala University, Uppsala, Sweden Department of Medicine Solna, Centre for Pharmacoepidemiology, Karolinska Institutet, Stockholm, Sweden
    Neuropsychiatr Dis Treat 9:371-7. 2013
  3. doi Factors associated with pregabalin dispensing at higher than the approved maximum dose
    Robert Boden
    Centre for Pharmacoepidemiology at the Department of Medicine, Karolinska Institutet, Stockholm, Sweden
    Eur J Clin Pharmacol 70:197-204. 2014
  4. pmc Risks of adverse pregnancy and birth outcomes in women treated or not treated with mood stabilisers for bipolar disorder: population based cohort study
    Robert Boden
    Department of Neuroscience, Psychiatry, Uppsala University, Ing 15 3tr, SE 751 85 Uppsala, Sweden
    BMJ 345:e7085. 2012
  5. doi Antipsychotics during pregnancy: relation to fetal and maternal metabolic effects
    Robert Boden
    Department of Medicine, Centre for Pharmacoepidemiology, Karolinska Institutet, Stockholm, Sweden
    Arch Gen Psychiatry 69:715-21. 2012
  6. doi Electrocardiographic signs of autonomic imbalance in medicated patients with first-episode schizophrenia spectrum disorders--relations to first treatment discontinuation and five-year remission status
    Robert Boden
    Department of Neuroscience Psychiatry, Uppsala University Hospital, 751 85 Uppsala, Sweden
    Eur Psychiatry 27:213-8. 2012
  7. doi Association between symptomatic remission and functional outcome in first-episode schizophrenia
    Robert Boden
    Department of Neuroscience, Psychiatry Ulleraker, Uppsala University Hospital, S 750 17, Uppsala, Sweden
    Schizophr Res 107:232-7. 2009
  8. doi Early non-adherence to medication and other risk factors for rehospitalization in schizophrenia and schizoaffective disorder
    Robert Boden
    Centre for Pharmacoepidemiology, Department of Medicine, Karolinska Institutet, Solna, Sweden
    Schizophr Res 133:36-41. 2011
  9. ncbi Medication and suicide risk in schizophrenia: a nested case-control study
    Johan Reutfors
    Centre for Pharmacoepidemiology CPE, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden Electronic address
    Schizophr Res 150:416-20. 2013
  10. doi Antipsychotic prescription filling in patients with schizophrenia or schizoaffective disorder
    Johan Reutfors
    From the Centre for Pharmacoepidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm and Department of Neuroscience, Psychiatry, Uppsala University, Uppsala, Sweden
    J Clin Psychopharmacol 33:759-65. 2013

Detail Information

Publications12

  1. doi Five-year outcome of first-episode psychosis before and after the implementation of a modified assertive community treatment programme
    Robert Boden
    Department of Neuroscience, Psychiatry Ulleraker, Uppsala University Hospital, 750 17, Uppsala, Sweden
    Soc Psychiatry Psychiatr Epidemiol 45:665-74. 2010
    ..We investigated whether the implementation of such a programme would improve symptomatic and functional outcome 5 years later...
  2. pmc A comparison of cardiovascular risk factors for ten antipsychotic drugs in clinical practice
    Robert Boden
    Department of Neuroscience, Psychiatry, Uppsala University, Uppsala, Sweden Department of Medicine Solna, Centre for Pharmacoepidemiology, Karolinska Institutet, Stockholm, Sweden
    Neuropsychiatr Dis Treat 9:371-7. 2013
    ..In conclusion, treatment with antipsychotic drugs is differentially associated with cardiovascular risk factors, even after adjusting for waist circumference, sex, age, and smoking...
  3. doi Factors associated with pregabalin dispensing at higher than the approved maximum dose
    Robert Boden
    Centre for Pharmacoepidemiology at the Department of Medicine, Karolinska Institutet, Stockholm, Sweden
    Eur J Clin Pharmacol 70:197-204. 2014
    ..Therefore, the aim of our study was to characterize patients dispensed pregabalin at higher than the maximum allowed dose in a cohort study based on data extracted from Swedish national registers...
  4. pmc Risks of adverse pregnancy and birth outcomes in women treated or not treated with mood stabilisers for bipolar disorder: population based cohort study
    Robert Boden
    Department of Neuroscience, Psychiatry, Uppsala University, Ing 15 3tr, SE 751 85 Uppsala, Sweden
    BMJ 345:e7085. 2012
    ..To investigate the risks of adverse pregnancy and birth outcomes for treated and untreated bipolar disorder during pregnancy...
  5. doi Antipsychotics during pregnancy: relation to fetal and maternal metabolic effects
    Robert Boden
    Department of Medicine, Centre for Pharmacoepidemiology, Karolinska Institutet, Stockholm, Sweden
    Arch Gen Psychiatry 69:715-21. 2012
    ..Knowledge about the effects of exposure to the newer antipsychotics during pregnancy is limited...
  6. doi Electrocardiographic signs of autonomic imbalance in medicated patients with first-episode schizophrenia spectrum disorders--relations to first treatment discontinuation and five-year remission status
    Robert Boden
    Department of Neuroscience Psychiatry, Uppsala University Hospital, 751 85 Uppsala, Sweden
    Eur Psychiatry 27:213-8. 2012
    ....
  7. doi Association between symptomatic remission and functional outcome in first-episode schizophrenia
    Robert Boden
    Department of Neuroscience, Psychiatry Ulleraker, Uppsala University Hospital, S 750 17, Uppsala, Sweden
    Schizophr Res 107:232-7. 2009
    ..83, p=0.04). In conclusion, core symptoms of schizophrenia have an important limiting effect on functioning and subjective life satisfaction in the early course of the illness...
  8. doi Early non-adherence to medication and other risk factors for rehospitalization in schizophrenia and schizoaffective disorder
    Robert Boden
    Centre for Pharmacoepidemiology, Department of Medicine, Karolinska Institutet, Solna, Sweden
    Schizophr Res 133:36-41. 2011
    ..In conclusion, we identified two potentially modifiable risk factors for rehospitalization: short duration of initial hospitalization and early non-adherence to medication...
  9. ncbi Medication and suicide risk in schizophrenia: a nested case-control study
    Johan Reutfors
    Centre for Pharmacoepidemiology CPE, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden Electronic address
    Schizophr Res 150:416-20. 2013
    ..Patients with schizophrenia are at increased risk of suicide, but data from controlled studies of pharmacotherapy in relation to suicide risk is limited...
  10. doi Antipsychotic prescription filling in patients with schizophrenia or schizoaffective disorder
    Johan Reutfors
    From the Centre for Pharmacoepidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm and Department of Neuroscience, Psychiatry, Uppsala University, Uppsala, Sweden
    J Clin Psychopharmacol 33:759-65. 2013
    ..Assessment of factors influencing antipsychotic prescription fills in the early phase of schizophrenia or schizoaffective disorder...
  11. doi Biochemical risk factors for development of obesity in first-episode schizophrenia
    Robert Boden
    Department of Neuroscience, Psychiatry Ulleraker, Uppsala University Hospital, S 750 17, Sweden
    Schizophr Res 115:141-5. 2009
    ..These observations open a new window to future research on the mechanisms underlying the development of obesity in schizophrenia...